CEO message18 Jan 2024 16:47
This is an extract from the half year report dated 30th MAY 2023 from our CEO, Total lies and manipulation.
Commenting on the results, Dr Jon Burrows, Chief Executive Officer of Oxford BioDynamics, said:
"The first half of our financial year saw excellent progress across the business. There was sustained growth in orders of EpiSwitch CiRT tests, which has continued post-period end. Overwhelming demand for the PSE blood test after announcement of its high accuracy performance led the Group to accelerate its development.
" overwhelming Demand for the PSE test" our CEO reports !!!!!!!
120 days aprox since product launch and aprox 140 tests sold !!!!!
just over 1 per day, not excactly overwhelming demand is it ?
too many snouts in the trough. New management needed with integrity, backbone and HONESTY !!!!